Intentionally developed to help protect against thrombotic events, providing unique versatility across the broadest range of patients in its class
Largest clinical development program of its class with more than 20 RCTs and 120,000-plus patients7-27
Dosing regimens optimized for each therapeutic indication
Proven efficacy and safety profile across the most indications — NVAF, CAD, PAD, DVT/PE initial and extended treatment, and VTE prophylaxis in acutely ill medical patients and after hip/knee replacement surgery
